Vanda Pharmaceuticals | VNDA - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 141.14M 564K 2026-06
AstraZeneca USD 1.55B 44K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Enanta Pharmaceuticals USD 212K 1000 2023-12
Halozyme Therapeutics USD 114.04M 4.48M 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 218.28M 1.76M 2026-06
J&J USD 2.41B 1.35M 2026-03
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.47B 4.93M 2026-03
Minerva Neurosciences USD 1000 0 2024-09
Moderna USD 391M 2M 2025-09
Novartis USD 1.91B 60K 2026-03
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 82.88M 1.41M 2026-03
Puma Biotechnology USD 5K 0 2024-06
Sanofi EUR 1.21B 8.25M 2026-03
Takeda JPY 1.58B 460K 2026-06
Teva Pharmaceutical Industries USD 1.16B 1000K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vanda Pharmaceuticals USD 58K 0 2024-12
Veracyte USD 79.79M 1000 2026-06